Sandbox: sadaf: Difference between revisions

Jump to navigation Jump to search
Line 1: Line 1:
==Differentiating Pancytopenia from Other Diseases==
== Differential Diagnosis ==
* There are no other mimickers of pancytopenia, as the diagnosis can be unequivocally established by laboratory testing ([[complete blood count]]).
Different causes of the bleeding disorders can be differentiated based on their clinical manifestation and laboratory findings.  


{|
These features have discussed in the below table:
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Category
{|  
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Condition
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Category
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Etiology
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Sub-category
! colspan="3" rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Mechanism
! colspan="2" rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Diseases
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Congenital
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |History
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Acquried
! colspan="6" align="center" style="background:#4479BA; color: #FFFFFF;" + |Clinical manifestation
! colspan="9" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Clinical manifestations
! colspan="5" align="center" style="background:#4479BA; color: #FFFFFF;" + |Laboratory testing
! colspan="8" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para−clinical findings
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Comments
! colspan="1" rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings
|-
|-
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Demography
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Mucosal bleeding
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |History
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Petechia
! colspan="3" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Symptoms
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Ecchymoses
| colspan="4" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Signs
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Menorrhagia
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hematoma
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hemarthrosis
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Platelet count
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Bleeding time (BT)
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Prothrombin time (PT)
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Activated partial thromboplastin time (aPTT)
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Thrombin time (TT)
|-
|-
! colspan="8" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab Findings
! rowspan="14" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Platelet disorders
! rowspan="7" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Thrombocytopenia]]
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Infection]]-Induced [[thrombocytopenia]]<span name="harr_c115s002s001s002p001"></span><span name="9100754"></span><ref name="pmid21325604">{{cite journal |vauthors=Neunert C, Lim W, Crowther M, Cohen A, Solberg L, Crowther MA |title=The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia |journal=Blood |volume=117 |issue=16 |pages=4190–207 |date=April 2011 |pmid=21325604 |doi=10.1182/blood-2010-08-302984 |url=}}</ref><ref name="pmid26906627">{{cite journal |vauthors=Karimi O, Goorhuis A, Schinkel J, Codrington J, Vreden SGS, Vermaat JS, Stijnis C, Grobusch MP |title=Thrombocytopenia and subcutaneous bleedings in a patient with Zika virus infection |journal=Lancet |volume=387 |issue=10022 |pages=939–940 |date=March 2016 |pmid=26906627 |doi=10.1016/S0140-6736(16)00502-X |url=}}</ref><ref name="pmid25600600">{{cite journal |vauthors=Zammarchi L, Stella G, Mantella A, Bartolozzi D, Tappe D, Günther S, Oestereich L, Cadar D, Muñoz-Fontela C, Bartoloni A, Schmidt-Chanasit J |title=Zika virus infections imported to Italy: clinical, immunological and virological findings, and public health implications |journal=J. Clin. Virol. |volume=63 |issue= |pages=32–5 |date=February 2015 |pmid=25600600 |doi=10.1016/j.jcv.2014.12.005 |url=}}</ref>
| align="left" style="background:#F5F5F5;" |
* History of prior infection
| align="center" style="background:#F5F5F5;" |+
| align="center" style="background:#F5F5F5;" |+
| align="center" style="background:#F5F5F5;" |+
| align="center" style="background:#F5F5F5;" |+
| align="center" style="background:#F5F5F5;" |+
| align="center" style="background:#F5F5F5;" |+
| align="center" style="background:#F5F5F5;" | ↓
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | −
|-
|-
! colspan="1" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Appearance
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Medication|Medications]]-Induced [[Thrombocytopenia|thrombocy]]<span name="harr_c115s002s001s003p001"></span><span name="9100757"></span>[[Thrombocytopenia|topenia]] <ref name="pmid25134884">{{cite journal |vauthors=Kam T, Alexander M |title=Drug-induced immune thrombocytopenia |journal=J Pharm Pract |volume=27 |issue=5 |pages=430–9 |date=October 2014 |pmid=25134884 |doi=10.1177/0897190014546099 |url=}}</ref><ref name="pmid23461497">{{cite journal |vauthors=Seco-Melantuche R, Delgado-Sánchez O, Álvarez-Arroyo L |title=[Incidence of drug-induced thrombocytopenia in hospitalized patients] |language=Spanish; Castilian |journal=Farm Hosp |volume=37 |issue=1 |pages=27–34 |date=2013 |pmid=23461497 |doi=10.7399/FH.2013.37.1.42 |url=}}</ref>
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever
| align="left" style="background:#F5F5F5;" |
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bleeding
*History of [[Medication|medications]] such as:
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |BP
** [[Furosemide]]
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Splenomegaly
** [[Non-steroidal anti-inflammatory drug|Nonsteroidal anti-inflammatory drugs]] ([[Non-steroidal anti-inflammatory drug|NSAIDs]])
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Jaundice
** [[Penicillin]]
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other
** [[Quinidine]]
! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |CBC
** [[Quinine]]
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |PBS
** [[Ranitidine]]
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bone marrow exam
** [[Sulfonamide (medicine)|Sulfonamides]]
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |PT
** [[Linezolid]]
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |PTT
| align="center" style="background:#F5F5F5;" | +
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |UA
| align="center" style="background:#F5F5F5;" |+
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Most important part of treatment is discontinuing of the medication.
|-
|-
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bone marrow infiltration
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Heparin-Induced Thrombocytopenia|Heparin-Induced thrombocytopenia]]<span name="harr_c115s002s001s004p001"></span><span name="9100761"></span><ref name="pmid25629757">{{cite journal |vauthors=Warkentin TE, Safyan EL, Linkins LA |title=Heparin-induced thrombocytopenia presenting as bilateral adrenal hemorrhages |journal=N. Engl. J. Med. |volume=372 |issue=5 |pages=492–4 |date=January 2015 |pmid=25629757 |doi=10.1056/NEJMc1414161 |url=}}</ref>
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bone marrow failure
| align="left" style="background:#F5F5F5;" |  
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Destruction/
* [[Thrombosis]]
sequestration/
* Unexplained [[thrombocytopenia]] up to 3 weeks after the end of [[heparin]] therapy
redistribution
| align="center" style="background:#F5F5F5;" | +
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Plt
| align="center" style="background:#F5F5F5;" | +
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |HB
| align="center" style="background:#F5F5F5;" | +
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |WBC
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | ↓
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | For more information click here: [[Heparin-induced thrombocytopenia]].
|-
|-
! rowspan="10" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Hematologic disorders
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Idiopathic thrombocytopenic purpura|Immune Thrombocytopenic Purpura]] ([[Idiopathic thrombocytopenic purpura|ITP]])<span name="harr_c115s002s001s005p001"></span><span name="9100771"></span><ref name="pmid8857953">{{cite journal |vauthors=Wright JF, Blanchette VS, Wang H, Arya N, Petric M, Semple JW, Chia WK, Freedman J |title=Characterization of platelet-reactive antibodies in children with varicella-associated acute immune thrombocytopenic purpura (ITP) |journal=Br. J. Haematol. |volume=95 |issue=1 |pages=145–52 |date=October 1996 |pmid=8857953 |doi= |url=}}</ref>
! align="center" style="background:#DCDCDC;" |[[Myelodysplastic syndrome (patient information)|Myelodysplastic syndrome]]
| align="left" style="background:#F5F5F5;" |  
| align="left" style="background:#F5F5F5;" |  
* [[Bone marrow]] infiltration
* History of prior [[infection]] or no history
* Ineffective [[hematopoiesis]]
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" | ±
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" |Elderly
| align="center" style="background:#F5F5F5;" |Exposure to
* [[Chemotherapy]]
* [[Radiation therapy]]
* [[Tobacco smoking|Tobacco smoke]]
| align="center" style="background:#F5F5F5;" |
* [[Petechia|Petechiae]]
* [[Purpura]]
* Diffuse erythematous [[rash]]
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | ↓
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | −
|-
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |Inherited [[Thrombocytopenia]]<span name="harr_c115s002s001s006p001"></span><span name="9100783"></span><ref name="pmid27025194">{{cite journal |vauthors=Johnson B, Fletcher SJ, Morgan NV |title=Inherited thrombocytopenia: novel insights into megakaryocyte maturation, proplatelet formation and platelet lifespan |journal=Platelets |volume=27 |issue=6 |pages=519–25 |date=September 2016 |pmid=27025194 |pmc=5000870 |doi=10.3109/09537104.2016.1148806 |url=}}</ref><ref name="pmid30103613">{{cite journal |vauthors=Wang Q, Cao L, Sheng G, Shen H, Ling J, Xie J, Ma Z, Yin J, Wang Z, Yu Z, Chen S, Zhao Y, Ruan C, Xia L, Jiang M |title=Application of High-Throughput Sequencing in the Diagnosis of Inherited Thrombocytopenia |journal=Clin. Appl. Thromb. Hemost. |volume= |issue= |pages=1076029618790696 |date=August 2018 |pmid=30103613 |doi=10.1177/1076029618790696 |url=}}</ref>
| align="left" style="background:#F5F5F5;" |
* Positive family history
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" | +
* [[Shortness of breath]]
| align="center" style="background:#F5F5F5;" | +
* [[Fatigue]]
| align="center" style="background:#F5F5F5;" | +
* [[Pallor]]
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" | Normal
*Ovalomacrocytosis
| align="center" style="background:#F5F5F5;" | Normal
*Basophilic stippling
| align="center" style="background:#F5F5F5;" | Normal
*[[Howell-Jolly body]]
| align="center" style="background:#F5F5F5;" |
*Dysplastic [[Neutrophil|neutrophils]]
| align="center" style="background:#F5F5F5;" |
*Impaired [[myeloid]] maturation
*[[Congenital dyserythropoietic anemia|Dyserythropoiesis]]
*Dysgranulopoiesis
*Dysmegakaryocytopoiesis
*Hypercellular [[bone marrow]]
*[[Fibrosis]]
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |[[Bone marrow examination]] + clinical manifestation
| align="center" style="background:#F5F5F5;" |
*Might transformed to [[acute leukemia]]
|-
|-
! align="left" style="background:#DCDCDC;" |Malignancies such as:
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Thrombotic thrombocytopenic purpura|Thrombotic Thrombocytopenic Purpura]] ([[Thrombotic thrombocytopenic purpura|TTP]])<span name="harr_c115s002s002s001p001"></span><span name="9100787"></span><ref name="pmid30220931">{{cite journal |vauthors=Knöbl P |title=Thrombotic thrombocytopenic purpura |journal=Memo |volume=11 |issue=3 |pages=220–226 |date=2018 |pmid=30220931 |doi=10.1007/s12254-018-0429-6 |url=}}</ref><ref name="pmid26386489">{{cite journal |vauthors=Mannucci PM, Cugno M |title=The complex differential diagnosis between thrombotic thrombocytopenic purpura and the atypical hemolytic uremic syndrome: Laboratory weapons and their impact on treatment choice and monitoring |journal=Thromb. Res. |volume=136 |issue=5 |pages=851–4 |date=November 2015 |pmid=26386489 |doi=10.1016/j.thromres.2015.09.007 |url=}}</ref>
* [[Acute leukemia]]
| align="left" style="background:#F5F5F5;" | History of:
* [[Chronic leukemia]]
*[[Cancer]]
* [[Multiple myeloma]]
*[[Bone marrow transplantation]]
* [[Metastasis|Metastatic cancer]]
*[[Pregnancy]]
| align="left" style="background:#F5F5F5;" + |
*[[Medication]]
* [[Bone marrow]] infiltration
**[[Platelet]] aggregation inhibitors ([[ticlopidine]] and [[clopidogrel]])
* Ineffective [[hematopoiesis]]
**Immunosuppressants ([[cyclosporine]], [[mitomycin]], [[tacrolimus]]/FK506, [[interferon|interferon-α]])
* Immune mediated
*[[HIV-1]] infection
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" + |±
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" + |±
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" + |Any, more in adults
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" | ↓
*Exposure to chemicals
| align="center" style="background:#F5F5F5;" | ↑
*[[Radiation therapy|Radiation]]
| align="center" style="background:#F5F5F5;" | Normal
*Pre-existent blood disorders
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" | Normal
* [[Petechia|Petechiae]]
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |
*[[Muscle weakness|Weakness]]
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |
*[[Pancytopenia]]
| align="center" style="background:#F5F5F5;" + |
*Blast cells
*
| align="center" style="background:#F5F5F5;" + |↑
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
*[[Hemoglobinuria]]
| align="center" style="background:#F5F5F5;" + |Bone marrow examination
| align="center" style="background:#F5F5F5;" + |
*[[Tumor lysis syndrome]]
*[[Infection]]
*[[CNS]] involvement
*[[Disseminated intravascular coagulation|DIC]]
|-
|-
! align="center" style="background:#DCDCDC;" |[[Myelofibrosis]]
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Hemolytic-uremic syndrome|Hemolytic Uremic Syndrome]]<span name="harr_c115s002s002s002p001"></span><span name="9100796"></span><ref name="pmid24365375">{{cite journal |vauthors=Webster K, Schnitzler E |title=Hemolytic uremic syndrome |journal=Handb Clin Neurol |volume=120 |issue= |pages=1113–23 |date=2014 |pmid=24365375 |doi=10.1016/B978-0-7020-4087-0.00075-9 |url=}}</ref><ref name="pmid25845294">{{cite journal |vauthors=Picard C, Burtey S, Bornet C, Curti C, Montana M, Vanelle P |title=Pathophysiology and treatment of typical and atypical hemolytic uremic syndrome |journal=Pathol. Biol. |volume=63 |issue=3 |pages=136–43 |date=June 2015 |pmid=25845294 |doi=10.1016/j.patbio.2015.03.001 |url=}}</ref>
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" |History of:
* [[Bone marrow]] infiltration
* [[Infections]]
| align="center" style="background:#F5F5F5;" + | +
* [[Malignancy]], [[chemotherapy]], and [[ionizing radiation]]
| align="center" style="background:#F5F5F5;" + | +
* [[Calcineurin inhibitor]]s and [[transplantation]]
| align="center" style="background:#F5F5F5;" + |
* [[Pregnancy]], [[HELLP syndrome]], and [[oral contraceptive pill]]
| align="center" style="background:#F5F5F5;" + | +
* [[Systemic lupus erythematosis]] 
| align="center" style="background:#F5F5F5;" + | +
* [[Antiphospholipid syndrome|Antiphospholipid antibody syndrome]]
| align="center" style="background:#F5F5F5;" + |Average 60 years old
* [[Glomerulopathy]]
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" | +
*Exposure to chemicals
| align="center" style="background:#F5F5F5;" | +
*[[Radiation therapy|Radiation]]
| align="center" style="background:#F5F5F5;" | +
*Pre-existent blood disorders
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" | +
* [[Pallor]]
| align="center" style="background:#F5F5F5;" | +
* Major [[weight loss]]
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" + |
|-
*[[Muscle weakness|Weakness]]
! align="center" style="padding: 5px 5px; background: #DCDCDC;" |Thromobcytosis
*[[Fatigue]]
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Iron deficiency anemia|Iron deficiency anemia]]
* [[Dyspnea|Shortness of breath]]
Inflammatory diseases
* [[Headache]]
 
| align="center" style="background:#F5F5F5;" + |
[[Splenectomy]]
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
*[[Pancytopenia]]
| align="center" style="background:#F5F5F5;" + |
* [[Pancytopenia]]


*Hypercellular [[bone marrow]]
[[Essential thrombocytosis|Essential thrombocytosis]]
*[[Fibrosis]]
| align="left" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" + |↑
* Digital [[pain]]
| align="center" style="background:#F5F5F5;" + |↑
* [[Gangrene]]
| align="center" style="background:#F5F5F5;" + |
* [[Erythromelalgia]]
*[[Hemoglobinuria]]
* H[[eadache]]
| align="center" style="background:#F5F5F5;" + |Bone marrow examination
* [[Paresthesia|Paresthesias]]
| align="center" style="background:#F5F5F5;" + |
* [[Transient ischemic attack|Transient ischemic attacks]]
* [[Cardiac arrhythmia|Arrhythmia]]
| align="center" style="background:#F5F5F5;" | −
* [[Infection]]
| align="center" style="background:#F5F5F5;" | −
* [[Seizure]]
| align="center" style="background:#F5F5F5;" | −
* May progress to malignancy
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | +/-
| align="center" style="background:#F5F5F5;" | +/-
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | Normal or
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | −
|-
! rowspan="6" align="center" style="padding: 5px 5px; background: #DCDCDC;" |Qualitative Disorders of [[Platelet]] Function<span name="harr_c115s002s004s001p001"></span><span name="9100803"></span>
! rowspan="4" align="center" style="padding: 5px 5px; background: #DCDCDC;" |Inherited Disorders of [[Platelet]] Function<span name="harr_c115s002s004s001p001"></span><span name="9100803"></span>
! align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Glanzmann's thrombasthenia|Glanzmann’s thrombasthenia]]
| align="left" style="background:#F5F5F5;" |
* Positive family history
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" | Rare
| align="center" style="background:#F5F5F5;" | Normal or ↓
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Normal
| align="left" style="background:#F5F5F5;" |
* AR inheritance
* Absence of the platelet Gp IIb/IIIa receptor
* Diminished for GP 2B-3A on [[Flow cytometry|flow cytometry]]  
|-
! align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Bernard-Soulier syndrome]]<ref name="pmid30077511">{{cite journal |vauthors=Dupuis A, Gachet C |title=Inherited platelet disorders : Management of the bleeding risk |journal=Transfus Clin Biol |volume=25 |issue=3 |pages=228–235 |date=September 2018 |pmid=30077511 |doi=10.1016/j.tracli.2018.07.003 |url=}}</ref><ref name="pmid29227167">{{cite journal |vauthors=Andres O, Henning K, Strauß G, Pflug A, Manukjan G, Schulze H |title=Diagnosis of platelet function disorders: A standardized, rational, and modular flow cytometric approach |journal=Platelets |volume=29 |issue=4 |pages=347–356 |date=June 2018 |pmid=29227167 |doi=10.1080/09537104.2017.1386297 |url=}}</ref>
| align="left" style="background:#F5F5F5;" |
* Positive family history
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | Normal/↓
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Normal
| align="left" style="background:#F5F5F5;" |
* AR inheritance
* Absence of the platelet Gp Ib-IX-V receptor
* On PBS: giant platelets
* Ristocetin - no aggregation
|-
! align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Wiskott-Aldrich syndrome]]<ref name="pmid23527934">{{cite journal |vauthors=Wang YQ, Cui YX, Feng J |title=[Clinical phenotype and gene diagnostic analysis of Omenn syndrome] |language=Chinese |journal=Zhonghua Er Ke Za Zhi |volume=51 |issue=1 |pages=64–8 |date=January 2013 |pmid=23527934 |doi= |url=}}</ref><ref name="pmid27340577">{{cite journal |vauthors=Patil RB, Shanmukhaiah C, Jijina F, Bamborde S, Wasekar N, Toshniwal M, Mohite A, Patil V |title=Wiskott-Aldrich Syndrome Presenting with JMML-Like Blood Picture and Normal Sized Platelets |journal=Case Rep Hematol |volume=2016 |issue= |pages=8230786 |date=2016 |pmid=27340577 |pmc=4906177 |doi=10.1155/2016/8230786 |url=}}</ref><ref name="pmid29348920">{{cite journal |vauthors=Kaneko R, Yamamoto S, Okamoto N, Akiyama K, Matsuno R, Toyama D, Hoshino A, Imai K, Isoyama K |title=Wiskott-Aldrich syndrome that was initially diagnosed as immune thrombocytopenic purpura secondary to a cytomegalovirus infection |journal=SAGE Open Med Case Rep |volume=6 |issue= |pages=2050313X17753788 |date=2018 |pmid=29348920 |pmc=5768273 |doi=10.1177/2050313X17753788 |url=}}</ref><ref name="pmid19084106">{{cite journal |vauthors=Ozcan E, Notarangelo LD, Geha RS |title=Primary immune deficiencies with aberrant IgE production |journal=J. Allergy Clin. Immunol. |volume=122 |issue=6 |pages=1054–62; quiz 1063–4 |date=December 2008 |pmid=19084106 |doi=10.1016/j.jaci.2008.10.023 |url=}}</ref>
| align="left" style="background:#F5F5F5;" |
* Positive family history
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | <nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | <nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | <nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | Normal or ↓
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Normal
| align="left" style="background:#F5F5F5;" |
* Anti-WASP antibody can be used to detect presence or absence of WAS protein
* In Wiskott–Aldrich syndrome, the [[Platelet|platelets]] are small and do not function properly. They are removed by the [[spleen]], which leads to low [[platelet]] counts.
|-
|-
! align="center" style="background:#DCDCDC;" |[[Fanconi anemia]]
! align="left" style="padding: 5px 5px; background: #DCDCDC;" |[[Platelet storage pool deficiency|Platelet storage pool disorder (SPD)]]:
| align="center" style="background:#F5F5F5;" + |
*[[Hermansky-Pudlak syndrome]]
* [[Genetic disorder|Genetic defect]]
*[[Chediak-Higashi syndrome]]
* [[Bone marrow suppression|Bone marrow failure]]
*[[Gray platelet syndrome]]
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" + | +
* Positive family history
| align="center" style="background:#F5F5F5;" + |−
* [[Hairy cell leukemia]]
| align="center" style="background:#F5F5F5;" + | +
* [[Cardiovascular bypass]]
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" + |Rare  [[autosomal recessive]] genetic disorder, higher in Ashkenazi Jews and Afrikaners in South Africa
| align="center" style="background:#F5F5F5;" | <nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" | <nowiki>+</nowiki>
* Family history of [[Fanconi anemia]]
| align="center" style="background:#F5F5F5;" | <nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" | −
* [[Short stature]]
| align="center" style="background:#F5F5F5;" |
* [[Petechia|Petechiae]] and [[Bruise|bruises]]
| align="center" style="background:#F5F5F5;" | Normal or ↓
* [[Pallor]]
| align="center" style="background:#F5F5F5;" |
* [[Skin changes|Skin discoloration]]
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" + |Nl
| align="left" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" + |−
* AD inheritance
| align="center" style="background:#F5F5F5;" + |
* Abnormalities of platelet granule formation
| align="center" style="background:#F5F5F5;" + |
|-
* Skeletal defects
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |Acquired Disorders of [[Platelet]] Function<span name="harr_c115s002s004s002p001"></span><span name="9100808"></span>
* Deafness
| align="left" style="background:#F5F5F5 |
* VSD
* [[Chronic renal failure pathophysiology|Uremia]]
* Kidney abnormalities
* [[Cardiopulmonary bypass]]
*
* Hematologic disorders such as: [[Myeloproliferative disease|myeloproliferative]] and [[Myelodysplastic syndrome|myelodysplastic syndromes]]
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" | <nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" | <nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" | <nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" | <nowiki>+</nowiki>
*[[Pancytopenia]]
| align="center" style="background:#F5F5F5;" | +/-
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" | +/-
* [[Pancytopenia]]
| align="center" style="background:#F5F5F5;" | Normal/↓
 
| align="center" style="background:#F5F5F5;" |
*Hypercellular [[bone marrow]]
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" + |Genetic studies
|-
| align="center" style="background:#F5F5F5;" + |
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Von Willebrand disease|Von Willebrand Disease]]<span name="harr_c115s002s005p001"></span><span name="9100810"></span> <ref name="pmid25196510">{{cite journal |vauthors=Elbatarny M, Mollah S, Grabell J, Bae S, Deforest M, Tuttle A, Hopman W, Clark DS, Mauer AC, Bowman M, Riddel J, Christopherson PA, Montgomery RR, Rand ML, Coller B, James PD |title=Normal range of bleeding scores for the ISTH-BAT: adult and pediatric data from the merging project |journal=Haemophilia |volume=20 |issue=6 |pages=831–5 |date=November 2014 |pmid=25196510 |pmc=4251588 |doi=10.1111/hae.12503 |url=}}</ref><ref name="pmid25196510">{{cite journal |vauthors=Elbatarny M, Mollah S, Grabell J, Bae S, Deforest M, Tuttle A, Hopman W, Clark DS, Mauer AC, Bowman M, Riddel J, Christopherson PA, Montgomery RR, Rand ML, Coller B, James PD |title=Normal range of bleeding scores for the ISTH-BAT: adult and pediatric data from the merging project |journal=Haemophilia |volume=20 |issue=6 |pages=831–5 |date=November 2014 |pmid=25196510 |pmc=4251588 |doi=10.1111/hae.12503 |url=}}</ref><ref name="pmid16985174">{{cite journal |vauthors=Goodeve A, Eikenboom J, Castaman G, Rodeghiero F, Federici AB, Batlle J, Meyer D, Mazurier C, Goudemand J, Schneppenheim R, Budde U, Ingerslev J, Habart D, Vorlova Z, Holmberg L, Lethagen S, Pasi J, Hill F, Hashemi Soteh M, Baronciani L, Hallden C, Guilliatt A, Lester W, Peake I |title=Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD) |journal=Blood |volume=109 |issue=1 |pages=112–21 |date=January 2007 |pmid=16985174 |doi=10.1182/blood-2006-05-020784 |url=}}</ref><ref name="pmid9579642">{{cite journal |vauthors=Mammen EF, Comp PC, Gosselin R, Greenberg C, Hoots WK, Kessler CM, Larkin EC, Liles D, Nugent DJ |title=PFA-100 system: a new method for assessment of platelet dysfunction |journal=Semin. Thromb. Hemost. |volume=24 |issue=2 |pages=195–202 |date=1998 |pmid=9579642 |doi=10.1055/s-2007-995840 |url=}}</ref><ref name="pmid258585642">{{cite journal |vauthors=Bodó I, Eikenboom J, Montgomery R, Patzke J, Schneppenheim R, Di Paola J |title=Platelet-dependent von Willebrand factor activity. Nomenclature and methodology: communication from the SSC of the ISTH |journal=J. Thromb. Haemost. |volume=13 |issue=7 |pages=1345–50 |date=July 2015 |pmid=25858564 |pmc=5576173 |doi=10.1111/jth.12964 |url=}}</ref>
* Progress to [[Acute myeloid leukemia|acute myelogenous leukemia]]
| align="left" style="background:#F5F5F5;" |  
* [[Neoplasm|Solid tumors]]
* Easy bruising
* [[Developmental abnormality|Developmental abnormalities]]
* [[Epistaxis]]
* Oral cavity bleeding
* Bleeding after dental extraction/surgery
* [[Menorrhagia]]
* [[Postpartum hemorrhage]]
| align="center" style="background:#F5F5F5;" | <nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | <nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | <nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" | <nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" +/-
| align="center" style="background:#F5F5F5;" |  +/-
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | See the table below for the details about different types.
|-
|-
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Condition
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Vessel wall disorders
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Etiology
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Metabolism|Metabolic]] and [[Inflammation|Inflammatory]] Disorders
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bone marrow infiltration
! align="left" style="padding: 5px 5px; background: #DCDCDC;" |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bone marrow failure
* Acute febrile illnesses
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Destruction/
* [[Cryoglobulinemia|Mixed cryoglobulinemia]]
sequestration/
* [[Monoclonal gammopathy|Monoclonal gammopathies]]
redistribution
* Certain pathogens, such as the rickettsiae causing [[Rocky Mountain spotted fever]]
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Congenital
* [[Vitamin C]] deficiency
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Acquried
* [[Cushing's syndrome|Cushing’s syndrome]]
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Demography
* Chronic [[glucocorticoid]] therapy
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |History
* [[Ageing|Aging]] 
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Appearance
* [[Vasculitis]] such as Henoch-Schönlein,
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever
|
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bleeding
* History of the underlying disease.
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |BP
|
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Splenomegaly
|<nowiki>+</nowiki>
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Jaundice
|<nowiki>+</nowiki>
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other signs
|<nowiki>+/-</nowiki>
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Plt
| -
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |HB
| -
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |WBC
|Normal
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PBS
|↑/Normal
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bone marrow exam
|Normal
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PT
|Normal
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PTT
|Normal
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |UA
|<nowiki>-</nowiki>
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings
|-
|-
! align="center" style="background:#DCDCDC;" |[[Aplastic anemia]]
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |Inherited Disorders of the [[Vessel wall|Vessel Wall]]
| align="center" style="background:#F5F5F5;" + |
! align="left" style="padding: 5px 5px; background: #DCDCDC;" |
*Unknown
* [[Marfan's syndrome|Marfan’s syndrome]]
| align="center" style="background:#F5F5F5;" + |
* [[Ehlers-Danlos syndrome]]
| align="center" style="background:#F5F5F5;" + | +
* [[Pseudoxanthoma elasticum]]
| align="center" style="background:#F5F5F5;" + |−
* [[Hereditary hemorrhagic telangiectasia]] ([[Hereditary hemorrhagic telangiectasia|HHT]], or [[Osler-Weber-Rendu|Osler-Weber-Rendu disease]])
| align="center" style="background:#F5F5F5;" + |±
|
| align="center" style="background:#F5F5F5;" + |±
* Positive family history
| align="center" style="background:#F5F5F5;" + |Biphasic (the young and the elderly)
|<nowiki>-</nowiki>
| align="center" style="background:#F5F5F5;" + |
|<nowiki>+</nowiki>
* Exposure to [[Radiation (medicine)|radiation]], drugs and chemicals, [[pregnancy]], [[Paroxysmal nocturnal hemoglobinuria|PNH]] and viral or [[Autoimmune disease|autoimmune]] causes
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" + |
|<nowiki>+/-</nowiki>
* [[Pallor]]
| -
| align="center" style="background:#F5F5F5;" + |−
| -
| align="center" style="background:#F5F5F5;" + | +
|Normal
| align="center" style="background:#F5F5F5;" + |Nl
|↑/Normal
| align="center" style="background:#F5F5F5;" + |−
|Normal
| align="center" style="background:#F5F5F5;" + |−
|Normal
| align="center" style="background:#F5F5F5;" + |
|Normal
*[[Shortness of breath]]
|<nowiki>-</nowiki>
*[[Fatigue]]
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |
*Large [[Red blood cell|RBCs]]
*Low [[Platelet|platelets]] and [[Granulocyte|granulocytes]]
| align="center" style="background:#F5F5F5;" + |
*Hypocellular [[bone marrow]]
*replacement of [[bone marrow]] by [[fat]]
| align="center" style="background:#F5F5F5;" + |↑
| align="center" style="background:#F5F5F5;" + |↑
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |[[Bone marrow examination]] +
laboratory findings
| align="center" style="background:#F5F5F5;" + |
*[[Fanconi anemia|Fanconi Anemia]]
*[[Dyskeratosis congenita]]
*[[Shwachman-Diamond syndrome|Schwachman-Diamond syndrome]]
*[[Preleukemia]]
|-
|-
! align="center" style="background:#DCDCDC;" |[[Paroxysmal nocturnal hemoglobinuria]]
! rowspan="12" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Coagulation factor disorders<ref name="pmid29027765">{{cite journal |vauthors=Karimi M, Peyvandi F, Naderi M, Shapiro A |title=Factor XIII deficiency diagnosis: Challenges and tools |journal=Int J Lab Hematol |volume=40 |issue=1 |pages=3–11 |date=February 2018 |pmid=29027765 |doi=10.1111/ijlh.12756 |url=}}</ref><ref name="pmid27590165">{{cite journal |vauthors=Peyvandi F, Garagiola I, Biguzzi E |title=Advances in the treatment of bleeding disorders |journal=J. Thromb. Haemost. |volume=14 |issue=11 |pages=2095–2106 |date=November 2016 |pmid=27590165 |doi=10.1111/jth.13491 |url=}}</ref><ref name="pmid28966616">{{cite journal |vauthors=Bender L, Weidmann H, Rose-John S, Renné T, Long AT |title=Factor XII-Driven Inflammatory Reactions with Implications for Anaphylaxis |journal=Front Immunol |volume=8 |issue= |pages=1115 |date=2017 |pmid=28966616 |pmc=5605561 |doi=10.3389/fimmu.2017.01115 |url=}}</ref><ref name="pmid28966616" /><ref name="pmid27380557">{{cite journal |vauthors=Schmaier AH |title=Antithrombotic potential of the contact activation pathway |journal=Curr. Opin. Hematol. |volume=23 |issue=5 |pages=445–52 |date=September 2016 |pmid=27380557 |pmc=5148823 |doi=10.1097/MOH.0000000000000271 |url=}}</ref><ref name="pmid26565070">{{cite journal |vauthors=Schmaier AH |title=The contact activation and kallikrein/kinin systems: pathophysiologic and physiologic activities |journal=J. Thromb. Haemost. |volume=14 |issue=1 |pages=28–39 |date=January 2016 |pmid=26565070 |doi=10.1111/jth.13194 |url=}}</ref><ref name="pmid20580091">{{cite journal |vauthors=Kaplan AP, Ghebrehiwet B |title=The plasma bradykinin-forming pathways and its interrelationships with complement |journal=Mol. Immunol. |volume=47 |issue=13 |pages=2161–9 |date=August 2010 |pmid=20580091 |doi=10.1016/j.molimm.2010.05.010 |url=}}</ref><ref name="pmid22185738">{{cite journal |vauthors=Zuraw BL, Christiansen SC |title=Pathophysiology of hereditary angioedema |journal=Am J Rhinol Allergy |volume=25 |issue=6 |pages=373–8 |date=2011 |pmid=22185738 |doi=10.2500/ajra.2011.25.3661 |url=}}</ref><ref name="pmid23629422">{{cite journal |vauthors=Quail MT |title=Prekallikrein deficiency |journal=J Pediatr Oncol Nurs |volume=30 |issue=4 |pages=198–204 |date=2013 |pmid=23629422 |doi=10.1177/1043454213487436 |url=}}</ref><ref name="pmid27894217">{{cite journal |vauthors=Dorgalaleh A, Alavi SE, Tabibian S, Soori S, Moradi E, Bamedi T, Asadi M, Jalalvand M, Shamsizadeh M |title=Diagnosis, clinical manifestations and management of rare bleeding disorders in Iran |journal=Hematology |volume=22 |issue=4 |pages=224–230 |date=May 2017 |pmid=27894217 |doi=10.1080/10245332.2016.1263007 |url=}}</ref><ref name="pmid29483100">{{cite journal |vauthors=Maas C, Renné T |title=Coagulation factor XII in thrombosis and inflammation |journal=Blood |volume=131 |issue=17 |pages=1903–1909 |date=April 2018 |pmid=29483100 |doi=10.1182/blood-2017-04-569111 |url=}}</ref>
| align="center" style="background:#F5F5F5;" + |
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Fibrinogen]] deficiency<ref name="pmid29844251">{{cite journal |vauthors=Tiscia GL, Margaglione M |title=Human Fibrinogen: Molecular and Genetic Aspects of Congenital Disorders |journal=Int J Mol Sci |volume=19 |issue=6 |pages= |date=May 2018 |pmid=29844251 |pmc=6032319 |doi=10.3390/ijms19061597 |url=}}</ref>
*Deficiency of [[complement]] regulatory proteins
! style="padding: 5px 5px; background: #DCDCDC;" |Different types of the [[fibrinogen]] disorders:
* [[Fibrinogen#Congenital afibrinogenemia|Congenital afibrinogenemia]]
* [[Fibrinogen#Congenital hypofibrinogenemia|Congenital hypofibrinogenemia]]
* [[Fibrinogen#Fibrinogen storage disease|Fibrinogen storage disease]]
* [[Fibrinogen#Congenital dysfibrinogenemia|Congenital dysfibrinogenemia]]
* [[Fibrinogen#Hereditary fibrinogen A.CE.B1-Chain amyloidosis|Hereditary fibrinogen Aα-Chain amyloidosis]]
* [[Fibrinogen#Acquired dysfibrinogenemia|Acquired dysfibrinogenemia]]
* [[Fibrinogen#Congenital hypodysfibrinogenemia|Congenital hypodysfibrinogenemia]][[Fibrinogen#Cryofibrinogenemia|Cryofibrinogenemia]]
* [[Fibrinogen#Acquired hypofibrinogenemia|Acquired hypofibrinogenemia]]
|
* [[Epistaxis]]
* Easy [[Bruise|bruising]]
* [[Menorrhagia]]
* [[Muscle]] bleeds
* [[Hemarthrosis]]
* [[Bleeding]] from the [[umbilical cord]] stump after birth
* Bleeding after [[dental surgery]] or tooth extraction
* Abnormal bleeding during or after injury, surgery, or childbirth


*[[Mutation|Mutations]]
* [[Gastrointestinal tract|Gastrointestinal]] [[hemorrhage]]
| align="center" style="background:#F5F5F5;" + | +
* [[Cerebral hemorrhage]]
| align="center" style="background:#F5F5F5;" + | +
* [[Thrombosis]]
| align="center" style="background:#F5F5F5;" + |−
|<nowiki>-</nowiki>
| align="center" style="background:#F5F5F5;" + |−
| -
| align="center" style="background:#F5F5F5;" + | +
| +
| align="center" style="background:#F5F5F5;" + |Any age
| +
(usually younger adults)
| +/-
| align="center" style="background:#F5F5F5;" + |
| +
*Sudden [[nocturnal]] [[hemoglobinuria]] with partial clearing during the day
|Normal
| align="center" style="background:#F5F5F5;" + |
|
* Normal
|
| align="center" style="background:#F5F5F5;" + |−
|
| align="center" style="background:#F5F5F5;" + |−
|
| align="center" style="background:#F5F5F5;" + |Nl
|
| align="center" style="background:#F5F5F5;" + |−
* Impaired fibrin cross linking or clot dissolution.
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |
*[[Thrombosis]]
*Smooth muscle [[dystonia]]
| align="center" style="background:#F5F5F5;" + |↓/Nl
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↓/Nl
| align="center" style="background:#F5F5F5;" + |
*[[Pancytopenia]]
| align="center" style="background:#F5F5F5;" + |
*Cellular [[Bone marrow|marrow]]
*[[Erythroid]] [[hyperplasia]]
*[[dyserythropoiesis]]


*Hypocellular marrow in certain stages of the disease
* The severity of bleeding in patients with fibrinogen disorders can be mild or severe, with higher bleeding risk in those with afibrinogenemia or lower levels of functional fibrinogen.  The age of onset is also variable, with earlier onset in those with more severe deficiency.
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |
*[[Hemoglobinuria]]
| align="center" style="background:#F5F5F5;" + |[[Flow cytometry]]
| align="center" style="background:#F5F5F5;" + |
*[[Chronic renal failure]]
*[[Pulmonary hypertension]]
*[[Aplastic anemia]]
|-
|-
! align="center" style="background:#DCDCDC;" |[[Disseminated intravascular coagulation]]
! colspan="3" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Prothrombin deficiency]]
| align="center" style="background:#F5F5F5;" + |
|
* Consumption
* Easy [[bruising]]
| align="center" style="background:#F5F5F5;" + |−
* [[Epistaxis]]
| align="center" style="background:#F5F5F5;" + |−
* Soft-tissue hemorrhage
| align="center" style="background:#F5F5F5;" + | +
* Excessive postoperative bleeding
| align="center" style="background:#F5F5F5;" + |−
* [[Menorrhagia]]
| align="center" style="background:#F5F5F5;" + | +
* Muscle [[Hematoma|hematomas]]
| align="center" style="background:#F5F5F5;" + |Any
* [[Hemarthrosis]]
| align="center" style="background:#F5F5F5;" + |
* [[Intracranial hemorrhage|Intracranial]] bleeding
* [[Infection]]
|
* [[Physical trauma|Trauma]]
|<nowiki>+</nowiki>
* [[Obstetrics]] complications
|<nowiki>+</nowiki>
* [[Cancer]]
|<nowiki>+</nowiki>
* [[Shock]]
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" + |
|<nowiki>+</nowiki>
* Acutely ill
|Normal
| align="center" style="background:#F5F5F5;" + | +
|Normal
| align="center" style="background:#F5F5F5;" + | +
|↑
| align="center" style="background:#F5F5F5;" + |↓
|↑
| align="center" style="background:#F5F5F5;" + |−
|
| align="center" style="background:#F5F5F5;" + | +
|<nowiki>-</nowiki>
| align="center" style="background:#F5F5F5;" + |
*[[Shortness of breath]]
*[[Fatigue]]
*[[Chest pain]]
| align="center" style="background:#F5F5F5;" + |↓/Nl
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↓/Nl
| align="center" style="background:#F5F5F5;" + |
*[[Pancytopenia]]
| align="center" style="background:#F5F5F5;" + |NA
| align="center" style="background:#F5F5F5;" + |↑
| align="center" style="background:#F5F5F5;" + |↑
| align="center" style="background:#F5F5F5;" + |
*[[Hemoglobinuria]]
| align="center" style="background:#F5F5F5;" + |Lab findings
| align="center" style="background:#F5F5F5;" + |
* High mortality rate
|-
|-
! align="center" style="background:#DCDCDC;" |Dyskeratosis congenital/telomere biology disorders
! colspan="3" rowspan="1" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Factor V deficiency]]
| align="center" style="background:#F5F5F5;" + |
|
* Aberrant [[telomere]] biology
* Excessive bruising with minor injuries
* Germline [[Mutation|mutations]]  
* [[Epistaxis]]
| align="center" style="background:#F5F5F5;" + |−
* [[Hemarthrosis]]  
| align="center" style="background:#F5F5F5;" + | +
* [[Menorrhagia]]
| align="center" style="background:#F5F5F5;" + |−
* [[Intracerebral hemorrhage|Intracerebral hemorrhages]]
| align="center" style="background:#F5F5F5;" + | +
* [[Pulmonary hemorrhage]]  
| align="center" style="background:#F5F5F5;" + |−
|
| align="center" style="background:#F5F5F5;" + |Rare genetic disorder
|_
| align="center" style="background:#F5F5F5;" + |
|<nowiki>+</nowiki>
* Family history
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" + |
| +
* [[Isolated congenital nail dysplasia|Nail dysplasia]]
| +
* Abnormal [[Human skin color|skin pigmentation]]
|Normal
| align="center" style="background:#F5F5F5;" + |−
|
| align="center" style="background:#F5F5F5;" + | +
|
| align="center" style="background:#F5F5F5;" + |Nl
|
| align="center" style="background:#F5F5F5;" + |−
|Normal
| align="center" style="background:#F5F5F5;" + | +
|The severity of bleeding is only partly related to the degree of factor V deficiency. Some patients with undetectable plasma levels of factor V experience only relatively mild bleeding.
| align="center" style="background:#F5F5F5;" + |
* [[Leukoplakia|Oral leukoplakia]]
* [[Shortness of breath]]
*[[Fatigue]]
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |
*[[Pancytopenia]]
| align="center" style="background:#F5F5F5;" + |
*Hypocellular [[bone marrow]]
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Clinical findings + genetic studies
| align="center" style="background:#F5F5F5;" + |
* Progress to [[Cancer|malignancy]]
* [[Idiopathic pulmonary fibrosis|Pulmonary fibrosis]]
* [[Hepato-biliary diseases|Liver disease]]
|-
|-
! align="center" style="background:#DCDCDC;" |[[Shwachman-Diamond syndrome]]
! colspan="3" rowspan="1" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Factor VII deficiency]]
| align="center" style="background:#F5F5F5;" + |
|
* Germline [[Mutation|mutations]]
* Easy [[Bruise|bruising]]
* [[Bone marrow suppression|Bone marrow failure]]
* Mucosal bleeding
| align="center" style="background:#F5F5F5;" + |−
* Postoperative bleeding
| align="center" style="background:#F5F5F5;" + | +
* [[Menorrhagia]]
| align="center" style="background:#F5F5F5;" + |−
* Soft tissue hematomas
| align="center" style="background:#F5F5F5;" + | +
* [[Thrombosis]]  
| align="center" style="background:#F5F5F5;" + |−
|
| align="center" style="background:#F5F5F5;" + |Rare genetic disorder
|
| align="center" style="background:#F5F5F5;" + |
|
* Family history
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" + |
| +
* Skeletal abnormalities
| +
* [[Short stature]]
|Normal
* [[Metaphyseal dysostosis mental retardation conductive deafness|Metaphyseal dysostosis]]
|
| align="center" style="background:#F5F5F5;" + |−
|
| align="center" style="background:#F5F5F5;" + | +
|Normal
| align="center" style="background:#F5F5F5;" + |Nl
|Normal
| align="center" style="background:#F5F5F5;" + |−
|Thrombosis occurs in inherited factor VII deficiency  most cases are associated with the administration of factor VII replacement therapy
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |
* [[Steatorrhea]]
* [[Delayed milestone|Growth retardation]]
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |
*[[Pancytopenia]]
| align="center" style="background:#F5F5F5;" + |
*Hypocellular [[bone marrow]]
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Clinical findings + genetic studies
| align="center" style="background:#F5F5F5;" + |
* [[Pancreatic insufficiency|Exocrine pancreatic insufficiency]]
* [[Delayed milestone|Growth retardation]]
* Increased frequency of [[Infection|infections]]
|-
|-
! rowspan="6" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Immunology/
! colspan="3" rowspan="1" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Factor X deficiency]]
Rheumatology
|
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Condition
* Prolonged bleeding following circumcision
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Etiology
 
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bone marrow infiltration
* Easy [[Bruise|bruising]]
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bone marrow failure
* [[Hematuria]]
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Destruction/
* [[Menorrhagia]]
sequestration/
* Abortion
redistribution
* Postpartum hemorrhage
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Congenital
* Epistaxis
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Acquried
* Pseudotumors
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Demography
* Intracranial bleeding
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |History
* Hemarthroses
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Appearance
|
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever
|<nowiki>+</nowiki>
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bleeding
| +
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |BP
| +
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Splenomegaly
| +
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Jaundice
| +
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other signs
|Normal
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Plt
|Normal
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |HB
|
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |WBC
|
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PBS
|Normal
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bone marrow exam
|<nowiki>-</nowiki>
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PT
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PTT
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |UA
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings
|-
|-
! align="center" style="background:#DCDCDC;" |[[SLE]]
! colspan="3" rowspan="1" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Factor XII|Factor XII deficiency]]
| align="center" style="background:#F5F5F5;" + |
|
* Immune mediated [[Bone marrow suppression|bone marrow failure]]
* Majority,asymptomatic
| align="center" style="background:#F5F5F5;" + |−
* Recurrent miscarriages
| align="center" style="background:#F5F5F5;" + | +
* Painful leg ulcers
| align="center" style="background:#F5F5F5;" + | +
|
| align="center" style="background:#F5F5F5;" + | +
|_
| align="center" style="background:#F5F5F5;" + | +
|_
| align="center" style="background:#F5F5F5;" + |More in young females
|_
| align="center" style="background:#F5F5F5;" + |
|_
* Family history
|_
| align="center" style="background:#F5F5F5;" + |
|Normal
* [[Rash|Skin rash]]
|Normal
| align="center" style="background:#F5F5F5;" + | +
|Normal
| align="center" style="background:#F5F5F5;" + | +
|↑
| align="center" style="background:#F5F5F5;" + |Nl to ↓
|Normal
| align="center" style="background:#F5F5F5;" + | +
|
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |
* [[Weight loss]]
* [[Oral ulcer|Mouth ulcers]]
* [[Chest pain]]
* [[Lymphadenopathy]]
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |
*[[Pancytopenia]]
| align="center" style="background:#F5F5F5;" + |
*Hypocellular [[bone marrow]]
| align="center" style="background:#F5F5F5;" + |↑
| align="center" style="background:#F5F5F5;" + |↑
| align="center" style="background:#F5F5F5;" + |
*[[Hemoglobinuria]]
*[[Proteinuria]]
| align="center" style="background:#F5F5F5;" + |Clinical findings + laboratory studies
| align="center" style="background:#F5F5F5;" + |
* Multi organ damage
* Poor prognosis
|-
|-
! align="center" style="background:#DCDCDC;" |[[Felty's syndrome|Felty syndrome]]
! colspan="3" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[High-molecular-weight kininogen|High molecular weight kininogen (HMWK)]] deficiency
| align="center" style="background:#F5F5F5;" + |
|
* Immune mediated [[Bone marrow suppression|bone marrow failure]]
* Possibility of positive family history of bleeding
| align="center" style="background:#F5F5F5;" + |−
|
| align="center" style="background:#F5F5F5;" + | +
|_
| align="center" style="background:#F5F5F5;" + |−
|_
| align="center" style="background:#F5F5F5;" + |−
|_
| align="center" style="background:#F5F5F5;" + | +
|_
| align="center" style="background:#F5F5F5;" + |Rare [[autoimmune disease]], more in females 50-70 years old
|_
| align="center" style="background:#F5F5F5;" + |
|Normal
* History of [[rheumatoid arthritis]]  
|Normal
| align="center" style="background:#F5F5F5;" + |
|Normal
* [[Pallor]]
|
* [[Hyperpigmentation|Skin hyperpigmentation]]
|Normal
| align="center" style="background:#F5F5F5;" + | +
|
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |
* Painful, stiff, and swollen [[Joint|joints]]
* [[Keratoconjunctivitis sicca]]
* [[Weight loss]]
* [[Fatigue]]
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |
*[[Pancytopenia]]
| align="center" style="background:#F5F5F5;" + |
*Hypocellular [[bone marrow]]
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Clinical findings + laboratory studies
| align="center" style="background:#F5F5F5;" + |
* [[Rheumatoid arthritis]]
* [[Infection|Infections]]
|-
|-
! align="center" style="background:#DCDCDC;" |[[Wiskott-Aldrich syndrome|Wiskott Aldrich syndrome]]
! colspan="3" rowspan="1" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Prekallikrein]] deficiency
| align="center" style="background:#F5F5F5;" + |
|
* Mutation in [[GATA1|GATA-1]]
* Possibility of positive family history of bleeding
* Immune mediated [[bone marrow failure]]
|
| align="center" style="background:#F5F5F5;" + |−
|_
| align="center" style="background:#F5F5F5;" + | +
|_
| align="center" style="background:#F5F5F5;" + |−
|_
| align="center" style="background:#F5F5F5;" + | +
|_
| align="center" style="background:#F5F5F5;" + |−
|_
| align="center" style="background:#F5F5F5;" + |Rare [[Sex-linked|X-linked]] [[Recessive gene|recessive]] disease
|Normal
| align="center" style="background:#F5F5F5;" + |
|Normal
* [[Immunodeficiency]]
|Normal
* Positive family history
|
| align="center" style="background:#F5F5F5;" + |
|Normal
*[[Eczema]]
|
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |
* [[Dysentery|Bloody diarrhea]]
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |
*[[Pancytopenia]]
| align="center" style="background:#F5F5F5;" + |
*Hypocellular [[bone marrow]]
*Small but low [[Platelet|platelets]]
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Genetic study
| align="center" style="background:#F5F5F5;" + |
*Recurrent [[Infection|infections]]
 
*[[Autoimmune disease|autoimmune disorders]]
*[[Cancer|Malignancy]]
|-
|-
! align="center" style="background:#DCDCDC;" |[[GATA2]] deficiency
! colspan="2" rowspan="1" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Factor XIII deficiency]]
| align="center" style="background:#F5F5F5;" + |
! style="padding: 5px 5px; background: #DCDCDC;" |Types:
* Immune mediated [[Bone marrow suppression|bone marrow failure]]
* Sub unit A mutation disease (more common)
| align="center" style="background:#F5F5F5;" + |−
* Sub unit B mutation disease
| align="center" style="background:#F5F5F5;" + | +
|
| align="center" style="background:#F5F5F5;" + |−
* Possibility of positive family history of bleeding
| align="center" style="background:#F5F5F5;" + | +
| -/+
| align="center" style="background:#F5F5F5;" + |−
| -/+
| align="center" style="background:#F5F5F5;" + |Rare
|<nowiki>-/+</nowiki>
| align="center" style="background:#F5F5F5;" + |
|<nowiki>-/+</nowiki>
* [[Immunodeficiency]]
|<nowiki>-/+</nowiki>
* Positive family history
|<nowiki>-/+</nowiki>
| align="center" style="background:#F5F5F5;" + |
|Normal
*[[Purpura]]
|Normal
*[[Petechia|Petechiae]]
|Normal/↑
| align="center" style="background:#F5F5F5;" + |−
|Normal
| align="center" style="background:#F5F5F5;" + | +
|Normal
| align="center" style="background:#F5F5F5;" + |↓
|
| align="center" style="background:#F5F5F5;" + | +
* Impaired fibrin cross linking or clot dissolution
| align="center" style="background:#F5F5F5;" + | +
* The severity of factor XIII deficiency bleeds can be different in different patients
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |
*[[Pancytopenia]]
| align="center" style="background:#F5F5F5;" + |
*Hypocellular [[bone marrow]]
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Genetic study
| align="center" style="background:#F5F5F5;" + |
*Recurrent [[Infection|infections]]
 
*[[Autoimmune disease|autoimmune disorders]]
*[[Cancer|Malignancy]]
|-
|-
! align="center" style="background:#DCDCDC;" |[[Hemophagocytic lymphohistiocytosis]]
! rowspan="3" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Hemophilia]]<ref name="pmid94489952">{{cite journal |vauthors=Aviña-Zubieta JA, Galindo-Rodriguez G, Lavalle C |title=Rheumatic manifestations of hematologic disorders |journal=Curr Opin Rheumatol |volume=10 |issue=1 |pages=86–90 |date=January 1998 |pmid=9448995 |doi= |url=}}</ref><ref name="pmid16551972">{{cite journal |vauthors=Plug I, Mauser-Bunschoten EP, Bröcker-Vriends AH, van Amstel HK, van der Bom JG, van Diemen-Homan JE, Willemse J, Rosendaal FR |title=Bleeding in carriers of hemophilia |journal=Blood |volume=108 |issue=1 |pages=52–6 |date=July 2006 |pmid=16551972 |doi=10.1182/blood-2005-09-3879 |url=}}</ref><ref name="pmid25059285">{{cite journal |vauthors=Blanchette VS, Key NS, Ljung LR, Manco-Johnson MJ, van den Berg HM, Srivastava A |title=Definitions in hemophilia: communication from the SSC of the ISTH |journal=J. Thromb. Haemost. |volume=12 |issue=11 |pages=1935–9 |date=November 2014 |pmid=25059285 |doi=10.1111/jth.12672 |url=}}</ref><ref name="pmid11307831">{{cite journal |vauthors=White GC, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J |title=Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis |journal=Thromb. Haemost. |volume=85 |issue=3 |pages=560 |date=March 2001 |pmid=11307831 |doi= |url=}}</ref><ref name="pmid24026910">{{cite journal |vauthors=Favaloro EJ, Meijer P, Jennings I, Sioufi J, Bonar RA, Kitchen DP, Kershaw G, Lippi G |title=Problems and solutions in laboratory testing for hemophilia |journal=Semin. Thromb. Hemost. |volume=39 |issue=7 |pages=816–33 |date=October 2013 |pmid=24026910 |doi=10.1055/s-0033-1356573 |url=}}</ref><ref name="pmid250592852">{{cite journal |vauthors=Blanchette VS, Key NS, Ljung LR, Manco-Johnson MJ, van den Berg HM, Srivastava A |title=Definitions in hemophilia: communication from the SSC of the ISTH |journal=J. Thromb. Haemost. |volume=12 |issue=11 |pages=1935–9 |date=November 2014 |pmid=25059285 |doi=10.1111/jth.12672 |url=}}</ref>
| align="center" style="background:#F5F5F5;" + |
* Immune mediated [[Bone marrow suppression|bone marrow failure]]
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |Rare
| align="center" style="background:#F5F5F5;" + |
* [[Immunodeficiency]]
* Positive family history
| align="center" style="background:#F5F5F5;" + |
*[[Purpura]]
*[[Petechia|Petechiae]]
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
*[[Pancytopenia]]
| align="center" style="background:#F5F5F5;" + |
*Hypocellular [[bone marrow]]
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Genetic study
| align="center" style="background:#F5F5F5;" + |
*Recurrent [[Infection|infections]]


*[[Autoimmune disease|autoimmune disorders]]
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |Type A deficiency
*[[Cancer|Malignancy]]
|
* Eeasy [[Bruise|bruising]]
* Inadequate clotting in [[trauma]] or mild injury
* Spontaneous hemorrhage
* [[Hemarthrosis]]
* [[Epistaxis]]
* [[Gingival bleeding]]
| -
| -
| -
| +
| +
|<nowiki>+</nowiki>
|Normal
|Normal
|Normal
|↑
|Normal
|<nowiki>-</nowiki>
|-
|-
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |GI disorders
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |Type B deficiency
! align="center" style="background:#DCDCDC;" |[[Portal hypertension]]/[[cirrhosis]]
|
| align="left" style="background:#F5F5F5;" + |
* Neonatal bleeding
* [[Splenomegaly]]
* Trauma-related soft-tissue hemorrhage
| align="center" style="background:#F5F5F5;" + |−
* [[Hemarthrosis]]
| align="center" style="background:#F5F5F5;" + |−
* [[Hematoma|Hematomas]]  
| align="center" style="background:#F5F5F5;" + | +
| -
| align="center" style="background:#F5F5F5;" + |−
| -
| align="center" style="background:#F5F5F5;" + | +
| -
| align="center" style="background:#F5F5F5;" + |Any
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" + |
| +
*[[Cirrhosis]]
|<nowiki>+</nowiki>
*[[Alcoholism|Alcohol use]]
|Normal
| align="center" style="background:#F5F5F5;" + |
|Normal
*[[Purpura]]
|Normal
*[[Petechia|Petechiae]]
|↑
| align="center" style="background:#F5F5F5;" + |−
|Normal
| align="center" style="background:#F5F5F5;" + | +
|<nowiki>-</nowiki>
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |
*[[Pancytopenia]]
| align="center" style="background:#F5F5F5;" + |
*Hypocellular [[bone marrow]]
| align="center" style="background:#F5F5F5;" + |↑
| align="center" style="background:#F5F5F5;" + |↑
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Clinical manifestation
| align="center" style="background:#F5F5F5;" + |
*[[Portal vein thrombosis]]
*[[Hepatorenal syndrome]]
*Variceal hemorrhage
*Hepatic [[hydrothorax]]
*[[Spontaneous bacterial peritonitis]]
|-
|-
! align="center" style="background:#DCDCDC;" |[[Glycogen storage disease|Storage diseases]] (eg, [[Gaucher's disease|Gaucher]])
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |Type C deficiency
| align="left" style="background:#F5F5F5;" + |
|
* [[Splenomegaly]]
* [[Bone marrow]] infiltration
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |Rare in children
| align="center" style="background:#F5F5F5;" + |
* Family history  
* Family history  
| align="center" style="background:#F5F5F5;" + |
* Bleeding after surgery or injury
* [[Rash|Skin rash]]
| -
| align="center" style="background:#F5F5F5;" + |−
| -
| align="center" style="background:#F5F5F5;" + | +
| -
| align="center" style="background:#F5F5F5;" + |↓
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" + | +
|Rare
| align="center" style="background:#F5F5F5;" + | +
|Rare
| align="center" style="background:#F5F5F5;" + |−
|Normal
| align="center" style="background:#F5F5F5;" + |↓
|Normal
| align="center" style="background:#F5F5F5;" + |↓
|Normal
| align="center" style="background:#F5F5F5;" + |↓
|
| align="center" style="background:#F5F5F5;" + |
|Normal
*[[Pancytopenia]]
| -
| align="center" style="background:#F5F5F5;" + |
*Hypocellular [[bone marrow]]
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Infections
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Rare diseases
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Condition
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Disseminated intravascular coagulation|Disseminated Intravascular Coagulation]]<ref name="pmid30008620">{{cite journal |vauthors=Wada H, Matsumoto T, Suzuki K, Imai H, Katayama N, Iba T, Matsumoto M |title=Differences and similarities between disseminated intravascular coagulation and thrombotic microangiopathy |journal=Thromb J |volume=16 |issue= |pages=14 |date=2018 |pmid=30008620 |pmc=6040080 |doi=10.1186/s12959-018-0168-2 |url=}}</ref>
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Etiology
! style="padding: 5px 5px; background: #DCDCDC;" |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bone marrow infiltration
* [[Trauma]]
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bone marrow failure
* Burn
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Destruction/
* [[Crush injury]]
sequestration/
* [[Sepsis]]
redistribution
* [[Malignancy]]
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Congenital
* Obstetric complication: abruption, amniotic fluid embolism
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Acquried
* [[Hemolytic anemia]]
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Demography
|<nowiki>+</nowiki>
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |History
| +
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Appearance
|<nowiki>+</nowiki>
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever
| +
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bleeding
|<nowiki>+</nowiki>
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |BP
|<nowiki>+</nowiki>
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Splenomegaly
|
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Jaundice
|
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other signs
|
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Plt
|
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |HB
|Normal
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |WBC
| -
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PBS
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bone marrow exam
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PT
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PTT
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |UA
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings
|-
|-
! align="center" style="background:#DCDCDC;" |[[Sepsis]]
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Vitamin K Deficiency]]<ref name="pmid26314836">{{cite journal |vauthors=Shiraishi E, Iijima H, Shinzaki S, Nakajima S, Inoue T, Hiyama S, Kawai S, Araki M, Yamaguchi T, Hayashi Y, Fujii H, Nishida T, Tsujii M, Takehara T |title=Vitamin K deficiency leads to exacerbation of murine dextran sulfate sodium-induced colitis |journal=J. Gastroenterol. |volume=51 |issue=4 |pages=346–56 |date=April 2016 |pmid=26314836 |doi=10.1007/s00535-015-1112-x |url=}}</ref>
| align="left" style="background:#F5F5F5;" + |
! style="padding: 5px 5px; background: #DCDCDC;" |
*Direct [[bone marrow suppression]]
* Bleeding after trauma
| align="center" style="background:#F5F5F5;" + | +
* [[Epistaxis]]
| align="center" style="background:#F5F5F5;" + | +
* [[Hematoma]]  
| align="center" style="background:#F5F5F5;" + |
* Gastrointestinal bleeding
| align="center" style="background:#F5F5F5;" + |−
* [[Menorrhagia]]  
| align="center" style="background:#F5F5F5;" + | +
* [[Hematuria]]
| align="center" style="background:#F5F5F5;" + |Any
* Gum bleeding
| align="center" style="background:#F5F5F5;" + |
* Oozing from venipuncture sites
*[[Infection|Bacterial infection]]
* Easy [[Bruise|bruisability]]
| align="center" style="background:#F5F5F5;" + |
|<nowiki>+</nowiki>
*[[Petechiae]]
| -
*[[Purpura]]
| +
*[[Erythema]]
| +
*[[Ulcer|Ulceration]]  
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" + | +
|<nowiki>+</nowiki>
| align="center" style="background:#F5F5F5;" + |±
|Normal
| align="center" style="background:#F5F5F5;" + |Nl to ↓
|↑
| align="center" style="background:#F5F5F5;" + |
|↑
| align="center" style="background:#F5F5F5;" + |±
|Normal or mildly prolonged
| align="center" style="background:#F5F5F5;" + |
|Normal
*[[Malaise]]
| -
*[[Lymphadenopathy]]
|}
| align="center" style="background:#F5F5F5;" + |↓/↑
Different types of Von-Willebrand diseases can be differentiated from each other based on the following table:<ref name="pmid258585643">{{cite journal |vauthors=Bodó I, Eikenboom J, Montgomery R, Patzke J, Schneppenheim R, Di Paola J |title=Platelet-dependent von Willebrand factor activity. Nomenclature and methodology: communication from the SSC of the ISTH |journal=J. Thromb. Haemost. |volume=13 |issue=7 |pages=1345–50 |date=July 2015 |pmid=25858564 |pmc=5576173 |doi=10.1111/jth.12964 |url=}}</ref>
| align="center" style="background:#F5F5F5;" + |
 
| align="center" style="background:#F5F5F5;" + |↓/↑
{|
| align="center" style="background:#F5F5F5;" + |
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Type of VWD
*[[Pancytopenia]]
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Type of factor deficiency
| align="center" style="background:#F5F5F5;" + |NA
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Prevalence
| align="center" style="background:#F5F5F5;" + |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Inheritance pattern
| align="center" style="background:#F5F5F5;" + |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Clinical manifestations
| align="center" style="background:#F5F5F5;" + | +
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |VWF activity
Depends on the etiology
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |RIPA
| align="center" style="background:#F5F5F5;" + |Clinical manifestation + culture
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Factor VIII
| align="center" style="background:#F5F5F5;" + |
*Associated with ↑ mortality
|-
|-
! align="center" style="background:#DCDCDC;" |[[Infection|Viral infection]] such as [[Human Immunodeficiency Virus (HIV)|HIV]], [[hepatitis]], [[Epstein Barr virus|Epstein-Barr virus]]
! colspan="2" align="center" style="background:#DCDCDC;" |Type 1
| align="left" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" | Quantitative/ partial
* [[Bone marrow suppression]]
| align="center" style="background:#F5F5F5;" | 60-70%
* [[Splenomegaly]]
| align="center" style="background:#F5F5F5;" | AD
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" + | +
* Bleeding severity mild to severe
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" | ↓
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" | ↓
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" | ↓
| align="center" style="background:#F5F5F5;" + |Any
| align="center" style="background:#F5F5F5;" + |
*High risk behaviors
*Close contact
| align="center" style="background:#F5F5F5;" + |
*[[Petechiae]]
*[[Purpura]]
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |±
| align="center" style="background:#F5F5F5;" + |±
| align="center" style="background:#F5F5F5;" + |
*[[Lymphadenopathy]]
*[[Muscle weakness]]
*[[Joint swelling]]
*Focal neurological deficits
*Depends on etiology
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |
*[[Pancytopenia]]
| align="center" style="background:#F5F5F5;" + |
*Hypocellular [[bone marrow]]
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |
*[[Hematuria]]
| align="center" style="background:#F5F5F5;" + |Clinical manifestation + lab tests
| align="center" style="background:#F5F5F5;" + |
*Depends on etiology
*[[Encephalomyelitis]]
|-
|-
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Nutritional
! rowspan="4" align="center" style="background:#DCDCDC;" |Type 2
! align="center" style="background:#DCDCDC;" |[[Macrocytic anemia|Megaloblastic anemia]]
! align="center" style="background:#DCDCDC;" |2A<ref name="pmid1537829">{{cite journal |vauthors=Lyons SE, Bruck ME, Bowie EJ, Ginsburg D |title=Impaired intracellular transport produced by a subset of type IIA von Willebrand disease mutations |journal=J. Biol. Chem. |volume=267 |issue=7 |pages=4424–30 |date=March 1992 |pmid=1537829 |doi= |url=}}</ref>
| align="left" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" | Qualitative
* Ineffective [[hematopoiesis]]
| align="center" style="background:#F5F5F5;" | 10%
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" | AD/AR
| align="center" style="background:#F5F5F5;" + | +
| align="left" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" + |−
* Moderate to severe [[bleeding]]
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" | ↓
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" | ↓
| align="center" style="background:#F5F5F5;" + |Any
| align="center" style="background:#F5F5F5;" | N or
| align="center" style="background:#F5F5F5;" + |
*[[Malnutrition]]
*[[Alcoholism|Alcohol use]]
| align="center" style="background:#F5F5F5;" + |
* Normal
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
*[[Fatigue]]
*[[Weakness]]
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |
*[[Pancytopenia]]
| align="center" style="background:#F5F5F5;" + |
*Hypocellular [[bone marrow]]
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Laboratory findings
| align="center" style="background:#F5F5F5;" + |NA
|-
|-
! align="center" style="background:#DCDCDC;" |Excessive [[alcohol]]
! align="center" style="background:#DCDCDC;" |2B
| align="left" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" | Qualitative
* Ineffective [[hematopoiesis]]
| align="center" style="background:#F5F5F5;" | 5%
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" | AD
| align="center" style="background:#F5F5F5;" + | +
| align="left" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" + |
* [[Thrombocytopenia]]
| align="center" style="background:#F5F5F5;" + |−
* Moderate to severe [[bleeding]]
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" | ↓
| align="center" style="background:#F5F5F5;" + |Alcoholism
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" | N or
*History of [[Alcoholism|alcohol use]]
| align="center" style="background:#F5F5F5;" + |
* Normal
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |
*[[Hepatomegaly]]
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |
*[[Pancytopenia]]
| align="center" style="background:#F5F5F5;" + |
*Hypocellular [[bone marrow]]
| align="center" style="background:#F5F5F5;" + |↑
| align="center" style="background:#F5F5F5;" + |↑
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Clinical manifestation
| align="center" style="background:#F5F5F5;" + |
*[[Chronic liver disease]]
|-
|-
! align="center" style="background:#DCDCDC;" |Other nutritional deficiency such as [[copper deficiency]], [[zinc]] toxicity
! align="center" style="background:#DCDCDC;" |2M
| align="left" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" | Qualitative
* Ineffective [[hematopoiesis]]
| align="center" style="background:#F5F5F5;" | <1%
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" | AD/AR
| align="center" style="background:#F5F5F5;" + | +
| align="left" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" + |
* Moderate to severe [[bleeding]]
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" | ↓
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" | ↓
| align="center" style="background:#F5F5F5;" + |Any
| align="center" style="background:#F5F5F5;" | N or
| align="center" style="background:#F5F5F5;" + |
*[[Malnutrition]]
*[[Alcoholism|Alcohol use]]
| align="center" style="background:#F5F5F5;" + |
* Normal
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |
*[[Fatigue]]
*[[Weakness]]
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |
*[[Pancytopenia]]
| align="center" style="background:#F5F5F5;" + |
*Hypocellular [[bone marrow]]
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Laboratory findings
| align="center" style="background:#F5F5F5;" + |NA
|-
|-
! align="center" style="background:#DCDCDC;" |[[Malnutrition]]
! align="center" style="background:#DCDCDC;" |2N
| align="left" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" | Qualitative
* Ineffective [[hematopoiesis]]
| align="center" style="background:#F5F5F5;" | <1%
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" | AR
| align="center" style="background:#F5F5F5;" + | +
| align="left" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" + |
* Clinically similar to [[hemophilia A]] with [[joint]], [[soft tissue]], [[urinary]] [[bleeding]]
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" | N
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" | N
| align="center" style="background:#F5F5F5;" + |Any
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" + |
*[[Malnutrition]]
*[[Alcoholism|Alcohol use]]
| align="center" style="background:#F5F5F5;" + |
* Normal
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |
*[[Fatigue]]
*[[Weakness]]
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |
*[[Pancytopenia]]
| align="center" style="background:#F5F5F5;" + |
*Hypocellular [[bone marrow]]
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Laboratory findings
| align="center" style="background:#F5F5F5;" + |NA
|-
|-
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Medications
! colspan="2" align="center" style="background:#DCDCDC;" |Type 3
! align="left" style="background:#DCDCDC;" |Medications such as:
| align="center" style="background:#F5F5F5;" | Complete deficiency
* [[Chemotherapy|Cytotoxic drugs]]
| align="center" style="background:#F5F5F5;" | 1-2%
* Idiosyncratic reactions to medications
| align="center" style="background:#F5F5F5;" | AR
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" |  
* Immune destruction
* Clinically similar to [[hemophilia A]] with [[joint]] and [[soft tissue]] [[bleeding]]
| align="center" style="background:#F5F5F5;" + |
* Severe [[mucosal bleeding]]
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" | Absent
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" | ↓
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" | Low, 1-10%
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Patients with [[Cancer|malignancy]]
| align="center" style="background:#F5F5F5;" + |
*[[Radiation therapy|Radiation]]
*[[Cancer]]
| align="center" style="background:#F5F5F5;" + |
*[[Purpura]]
*[[Petechia|Petechiae]]
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |
*[[Pancytopenia]]
| align="center" style="background:#F5F5F5;" + |
*Hypocellular [[bone marrow]]
*Megakaryocytic hypoplasia or aplasia
| align="center" style="background:#F5F5F5;" + |↑
| align="center" style="background:#F5F5F5;" + |↑
| align="center" style="background:#F5F5F5;" + |[[Hematuria case study one|Hematuria]]
| align="center" style="background:#F5F5F5;" + |Clinical manifestation + exclusion of the other causes
| align="center" style="background:#F5F5F5;" + |
*[[Thrombosis]]
|-
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Category
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Condition
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Etiology
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bone marrow infiltration
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bone marrow failure
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Destruction/
sequestration/
redistribution
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Congenital
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Acquried
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Demography
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |History
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Appearance
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bleeding
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |BP
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Splenomegaly
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Jaundice
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other signs
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Plt
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |HB
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |WBC
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PBS
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bone marrow exam
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PT
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PTT
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |UA
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings
|}
|}
<references />
For more information on Von Willebrand disease, click [[ von willebrand disease | here]].

Revision as of 15:50, 19 October 2018

Differential Diagnosis

Different causes of the bleeding disorders can be differentiated based on their clinical manifestation and laboratory findings.

These features have discussed in the below table:

Category Sub-category Diseases History Clinical manifestation Laboratory testing Comments
Mucosal bleeding Petechia Ecchymoses Menorrhagia Hematoma Hemarthrosis Platelet count Bleeding time (BT) Prothrombin time (PT) Activated partial thromboplastin time (aPTT) Thrombin time (TT)
Platelet disorders Thrombocytopenia Infection-Induced thrombocytopenia[1][2][3]
  • History of prior infection
+ + + + + + Normal Normal Normal
Medications-Induced thrombocytopenia [4][5] + + + + + + Normal Normal Normal Most important part of treatment is discontinuing of the medication.
Heparin-Induced thrombocytopenia[6] + + + + + + Normal Normal For more information click here: Heparin-induced thrombocytopenia.
Immune Thrombocytopenic Purpura (ITP)[7] + + + + + + Normal Normal Normal
Inherited Thrombocytopenia[8][9]
  • Positive family history
+ + + + + + Normal Normal Normal
Thrombotic Thrombocytopenic Purpura (TTP)[10][11] History of: + + + + + + Normal Normal Normal
Hemolytic Uremic Syndrome[12][13] History of: + + + + + + Normal Normal Normal
Thromobcytosis Iron deficiency anemia

Inflammatory diseases

Splenectomy

Essential thrombocytosis

+/- +/- Normal or ↑ Normal Normal Normal
Qualitative Disorders of Platelet Function Inherited Disorders of Platelet Function Glanzmann’s thrombasthenia
  • Positive family history
+ + + + Rare Normal or ↓ Normal Normal Normal
  • AR inheritance
  • Absence of the platelet Gp IIb/IIIa receptor
  • Diminished for GP 2B-3A on flow cytometry
Bernard-Soulier syndrome[14][15]
  • Positive family history
+ + + + Normal/↓ Normal Normal Normal
  • AR inheritance
  • Absence of the platelet Gp Ib-IX-V receptor
  • On PBS: giant platelets
  • Ristocetin - no aggregation
Wiskott-Aldrich syndrome[16][17][18][19]
  • Positive family history
+ + + + Normal or ↓ Normal Normal Normal
  • Anti-WASP antibody can be used to detect presence or absence of WAS protein
  • In Wiskott–Aldrich syndrome, the platelets are small and do not function properly. They are removed by the spleen, which leads to low platelet counts.
Platelet storage pool disorder (SPD): + + + + Normal or ↓ Normal Normal Normal
  • AD inheritance
  • Abnormalities of platelet granule formation
Acquired Disorders of Platelet Function + + + + +/- +/- Normal/↓ Normal Normal Normal
Von Willebrand Disease [20][20][21][22][23] + + + + +/- +/- Normal Normal See the table below for the details about different types.
Vessel wall disorders Metabolic and Inflammatory Disorders
  • History of the underlying disease.
+ + +/- - - Normal ↑/Normal Normal Normal Normal -
Inherited Disorders of the Vessel Wall
  • Positive family history
- + + +/- - - Normal ↑/Normal Normal Normal Normal -
Coagulation factor disorders[24][25][26][26][27][28][29][30][31][32][33] Fibrinogen deficiency[34] Different types of the fibrinogen disorders: - - + + +/- + Normal
  • Impaired fibrin cross linking or clot dissolution.
  • The severity of bleeding in patients with fibrinogen disorders can be mild or severe, with higher bleeding risk in those with afibrinogenemia or lower levels of functional fibrinogen. The age of onset is also variable, with earlier onset in those with more severe deficiency.
Prothrombin deficiency + + + + + Normal Normal -
Factor V deficiency _ + + + + Normal Normal The severity of bleeding is only partly related to the degree of factor V deficiency. Some patients with undetectable plasma levels of factor V experience only relatively mild bleeding.
Factor VII deficiency + + + Normal Normal Normal Thrombosis occurs in inherited factor VII deficiency most cases are associated with the administration of factor VII replacement therapy
Factor X deficiency
  • Prolonged bleeding following circumcision
+ + + + + Normal Normal Normal -
Factor XII deficiency
  • Majority,asymptomatic
  • Recurrent miscarriages
  • Painful leg ulcers
_ _ _ _ _ Normal Normal Normal Normal
High molecular weight kininogen (HMWK) deficiency
  • Possibility of positive family history of bleeding
_ _ _ _ _ Normal Normal Normal Normal
Prekallikrein deficiency
  • Possibility of positive family history of bleeding
_ _ _ _ _ Normal Normal Normal Normal
Factor XIII deficiency Types:
  • Sub unit A mutation disease (more common)
  • Sub unit B mutation disease
  • Possibility of positive family history of bleeding
-/+ -/+ -/+ -/+ -/+ -/+ Normal Normal Normal/↑ Normal Normal
  • Impaired fibrin cross linking or clot dissolution
  • The severity of factor XIII deficiency bleeds can be different in different patients
Hemophilia[35][36][37][38][39][40] Type A deficiency - - - + + + Normal Normal Normal Normal -
Type B deficiency - - - + + + Normal Normal Normal Normal -
Type C deficiency
  • Family history
  • Bleeding after surgery or injury
- - - + Rare Rare Normal Normal Normal Normal -
Rare diseases Disseminated Intravascular Coagulation[41] + + + + + + Normal -
Vitamin K Deficiency[42] + - + + + + Normal Normal or mildly prolonged Normal -

Different types of Von-Willebrand diseases can be differentiated from each other based on the following table:[43]

Type of VWD Type of factor deficiency Prevalence Inheritance pattern Clinical manifestations VWF activity RIPA Factor VIII
Type 1 Quantitative/ partial 60-70% AD
  • Bleeding severity mild to severe
Type 2 2A[44] Qualitative 10% AD/AR N or ↓
2B Qualitative 5% AD N or ↓
2M Qualitative <1% AD/AR N or ↓
2N Qualitative <1% AR N N
Type 3 Complete deficiency 1-2% AR Absent Low, 1-10%

For more information on Von Willebrand disease, click here.

  1. Neunert C, Lim W, Crowther M, Cohen A, Solberg L, Crowther MA (April 2011). "The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia". Blood. 117 (16): 4190–207. doi:10.1182/blood-2010-08-302984. PMID 21325604.
  2. Karimi O, Goorhuis A, Schinkel J, Codrington J, Vreden S, Vermaat JS, Stijnis C, Grobusch MP (March 2016). "Thrombocytopenia and subcutaneous bleedings in a patient with Zika virus infection". Lancet. 387 (10022): 939–940. doi:10.1016/S0140-6736(16)00502-X. PMID 26906627. Vancouver style error: initials (help)
  3. Zammarchi L, Stella G, Mantella A, Bartolozzi D, Tappe D, Günther S, Oestereich L, Cadar D, Muñoz-Fontela C, Bartoloni A, Schmidt-Chanasit J (February 2015). "Zika virus infections imported to Italy: clinical, immunological and virological findings, and public health implications". J. Clin. Virol. 63: 32–5. doi:10.1016/j.jcv.2014.12.005. PMID 25600600.
  4. Kam T, Alexander M (October 2014). "Drug-induced immune thrombocytopenia". J Pharm Pract. 27 (5): 430–9. doi:10.1177/0897190014546099. PMID 25134884.
  5. Seco-Melantuche R, Delgado-Sánchez O, Álvarez-Arroyo L (2013). "[Incidence of drug-induced thrombocytopenia in hospitalized patients]". Farm Hosp (in Spanish; Castilian). 37 (1): 27–34. doi:10.7399/FH.2013.37.1.42. PMID 23461497.
  6. Warkentin TE, Safyan EL, Linkins LA (January 2015). "Heparin-induced thrombocytopenia presenting as bilateral adrenal hemorrhages". N. Engl. J. Med. 372 (5): 492–4. doi:10.1056/NEJMc1414161. PMID 25629757.
  7. Wright JF, Blanchette VS, Wang H, Arya N, Petric M, Semple JW, Chia WK, Freedman J (October 1996). "Characterization of platelet-reactive antibodies in children with varicella-associated acute immune thrombocytopenic purpura (ITP)". Br. J. Haematol. 95 (1): 145–52. PMID 8857953.
  8. Johnson B, Fletcher SJ, Morgan NV (September 2016). "Inherited thrombocytopenia: novel insights into megakaryocyte maturation, proplatelet formation and platelet lifespan". Platelets. 27 (6): 519–25. doi:10.3109/09537104.2016.1148806. PMC 5000870. PMID 27025194.
  9. Wang Q, Cao L, Sheng G, Shen H, Ling J, Xie J, Ma Z, Yin J, Wang Z, Yu Z, Chen S, Zhao Y, Ruan C, Xia L, Jiang M (August 2018). "Application of High-Throughput Sequencing in the Diagnosis of Inherited Thrombocytopenia". Clin. Appl. Thromb. Hemost.: 1076029618790696. doi:10.1177/1076029618790696. PMID 30103613.
  10. Knöbl P (2018). "Thrombotic thrombocytopenic purpura". Memo. 11 (3): 220–226. doi:10.1007/s12254-018-0429-6. PMID 30220931.
  11. Mannucci PM, Cugno M (November 2015). "The complex differential diagnosis between thrombotic thrombocytopenic purpura and the atypical hemolytic uremic syndrome: Laboratory weapons and their impact on treatment choice and monitoring". Thromb. Res. 136 (5): 851–4. doi:10.1016/j.thromres.2015.09.007. PMID 26386489.
  12. Webster K, Schnitzler E (2014). "Hemolytic uremic syndrome". Handb Clin Neurol. 120: 1113–23. doi:10.1016/B978-0-7020-4087-0.00075-9. PMID 24365375.
  13. Picard C, Burtey S, Bornet C, Curti C, Montana M, Vanelle P (June 2015). "Pathophysiology and treatment of typical and atypical hemolytic uremic syndrome". Pathol. Biol. 63 (3): 136–43. doi:10.1016/j.patbio.2015.03.001. PMID 25845294.
  14. Dupuis A, Gachet C (September 2018). "Inherited platelet disorders : Management of the bleeding risk". Transfus Clin Biol. 25 (3): 228–235. doi:10.1016/j.tracli.2018.07.003. PMID 30077511.
  15. Andres O, Henning K, Strauß G, Pflug A, Manukjan G, Schulze H (June 2018). "Diagnosis of platelet function disorders: A standardized, rational, and modular flow cytometric approach". Platelets. 29 (4): 347–356. doi:10.1080/09537104.2017.1386297. PMID 29227167.
  16. Wang YQ, Cui YX, Feng J (January 2013). "[Clinical phenotype and gene diagnostic analysis of Omenn syndrome]". Zhonghua Er Ke Za Zhi (in Chinese). 51 (1): 64–8. PMID 23527934.
  17. Patil RB, Shanmukhaiah C, Jijina F, Bamborde S, Wasekar N, Toshniwal M, Mohite A, Patil V (2016). "Wiskott-Aldrich Syndrome Presenting with JMML-Like Blood Picture and Normal Sized Platelets". Case Rep Hematol. 2016: 8230786. doi:10.1155/2016/8230786. PMC 4906177. PMID 27340577.
  18. Kaneko R, Yamamoto S, Okamoto N, Akiyama K, Matsuno R, Toyama D, Hoshino A, Imai K, Isoyama K (2018). "Wiskott-Aldrich syndrome that was initially diagnosed as immune thrombocytopenic purpura secondary to a cytomegalovirus infection". SAGE Open Med Case Rep. 6: 2050313X17753788. doi:10.1177/2050313X17753788. PMC 5768273. PMID 29348920.
  19. Ozcan E, Notarangelo LD, Geha RS (December 2008). "Primary immune deficiencies with aberrant IgE production". J. Allergy Clin. Immunol. 122 (6): 1054–62, quiz 1063–4. doi:10.1016/j.jaci.2008.10.023. PMID 19084106.
  20. 20.0 20.1 Elbatarny M, Mollah S, Grabell J, Bae S, Deforest M, Tuttle A, Hopman W, Clark DS, Mauer AC, Bowman M, Riddel J, Christopherson PA, Montgomery RR, Rand ML, Coller B, James PD (November 2014). "Normal range of bleeding scores for the ISTH-BAT: adult and pediatric data from the merging project". Haemophilia. 20 (6): 831–5. doi:10.1111/hae.12503. PMC 4251588. PMID 25196510.
  21. Goodeve A, Eikenboom J, Castaman G, Rodeghiero F, Federici AB, Batlle J, Meyer D, Mazurier C, Goudemand J, Schneppenheim R, Budde U, Ingerslev J, Habart D, Vorlova Z, Holmberg L, Lethagen S, Pasi J, Hill F, Hashemi Soteh M, Baronciani L, Hallden C, Guilliatt A, Lester W, Peake I (January 2007). "Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD)". Blood. 109 (1): 112–21. doi:10.1182/blood-2006-05-020784. PMID 16985174.
  22. Mammen EF, Comp PC, Gosselin R, Greenberg C, Hoots WK, Kessler CM, Larkin EC, Liles D, Nugent DJ (1998). "PFA-100 system: a new method for assessment of platelet dysfunction". Semin. Thromb. Hemost. 24 (2): 195–202. doi:10.1055/s-2007-995840. PMID 9579642.
  23. Bodó I, Eikenboom J, Montgomery R, Patzke J, Schneppenheim R, Di Paola J (July 2015). "Platelet-dependent von Willebrand factor activity. Nomenclature and methodology: communication from the SSC of the ISTH". J. Thromb. Haemost. 13 (7): 1345–50. doi:10.1111/jth.12964. PMC 5576173. PMID 25858564.
  24. Karimi M, Peyvandi F, Naderi M, Shapiro A (February 2018). "Factor XIII deficiency diagnosis: Challenges and tools". Int J Lab Hematol. 40 (1): 3–11. doi:10.1111/ijlh.12756. PMID 29027765.
  25. Peyvandi F, Garagiola I, Biguzzi E (November 2016). "Advances in the treatment of bleeding disorders". J. Thromb. Haemost. 14 (11): 2095–2106. doi:10.1111/jth.13491. PMID 27590165.
  26. 26.0 26.1 Bender L, Weidmann H, Rose-John S, Renné T, Long AT (2017). "Factor XII-Driven Inflammatory Reactions with Implications for Anaphylaxis". Front Immunol. 8: 1115. doi:10.3389/fimmu.2017.01115. PMC 5605561. PMID 28966616.
  27. Schmaier AH (September 2016). "Antithrombotic potential of the contact activation pathway". Curr. Opin. Hematol. 23 (5): 445–52. doi:10.1097/MOH.0000000000000271. PMC 5148823. PMID 27380557.
  28. Schmaier AH (January 2016). "The contact activation and kallikrein/kinin systems: pathophysiologic and physiologic activities". J. Thromb. Haemost. 14 (1): 28–39. doi:10.1111/jth.13194. PMID 26565070.
  29. Kaplan AP, Ghebrehiwet B (August 2010). "The plasma bradykinin-forming pathways and its interrelationships with complement". Mol. Immunol. 47 (13): 2161–9. doi:10.1016/j.molimm.2010.05.010. PMID 20580091.
  30. Zuraw BL, Christiansen SC (2011). "Pathophysiology of hereditary angioedema". Am J Rhinol Allergy. 25 (6): 373–8. doi:10.2500/ajra.2011.25.3661. PMID 22185738.
  31. Quail MT (2013). "Prekallikrein deficiency". J Pediatr Oncol Nurs. 30 (4): 198–204. doi:10.1177/1043454213487436. PMID 23629422.
  32. Dorgalaleh A, Alavi SE, Tabibian S, Soori S, Moradi E, Bamedi T, Asadi M, Jalalvand M, Shamsizadeh M (May 2017). "Diagnosis, clinical manifestations and management of rare bleeding disorders in Iran". Hematology. 22 (4): 224–230. doi:10.1080/10245332.2016.1263007. PMID 27894217.
  33. Maas C, Renné T (April 2018). "Coagulation factor XII in thrombosis and inflammation". Blood. 131 (17): 1903–1909. doi:10.1182/blood-2017-04-569111. PMID 29483100.
  34. Tiscia GL, Margaglione M (May 2018). "Human Fibrinogen: Molecular and Genetic Aspects of Congenital Disorders". Int J Mol Sci. 19 (6). doi:10.3390/ijms19061597. PMC 6032319. PMID 29844251.
  35. Aviña-Zubieta JA, Galindo-Rodriguez G, Lavalle C (January 1998). "Rheumatic manifestations of hematologic disorders". Curr Opin Rheumatol. 10 (1): 86–90. PMID 9448995.
  36. Plug I, Mauser-Bunschoten EP, Bröcker-Vriends AH, van Amstel HK, van der Bom JG, van Diemen-Homan JE, Willemse J, Rosendaal FR (July 2006). "Bleeding in carriers of hemophilia". Blood. 108 (1): 52–6. doi:10.1182/blood-2005-09-3879. PMID 16551972.
  37. Blanchette VS, Key NS, Ljung LR, Manco-Johnson MJ, van den Berg HM, Srivastava A (November 2014). "Definitions in hemophilia: communication from the SSC of the ISTH". J. Thromb. Haemost. 12 (11): 1935–9. doi:10.1111/jth.12672. PMID 25059285.
  38. White GC, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J (March 2001). "Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis". Thromb. Haemost. 85 (3): 560. PMID 11307831.
  39. Favaloro EJ, Meijer P, Jennings I, Sioufi J, Bonar RA, Kitchen DP, Kershaw G, Lippi G (October 2013). "Problems and solutions in laboratory testing for hemophilia". Semin. Thromb. Hemost. 39 (7): 816–33. doi:10.1055/s-0033-1356573. PMID 24026910.
  40. Blanchette VS, Key NS, Ljung LR, Manco-Johnson MJ, van den Berg HM, Srivastava A (November 2014). "Definitions in hemophilia: communication from the SSC of the ISTH". J. Thromb. Haemost. 12 (11): 1935–9. doi:10.1111/jth.12672. PMID 25059285.
  41. Wada H, Matsumoto T, Suzuki K, Imai H, Katayama N, Iba T, Matsumoto M (2018). "Differences and similarities between disseminated intravascular coagulation and thrombotic microangiopathy". Thromb J. 16: 14. doi:10.1186/s12959-018-0168-2. PMC 6040080. PMID 30008620.
  42. Shiraishi E, Iijima H, Shinzaki S, Nakajima S, Inoue T, Hiyama S, Kawai S, Araki M, Yamaguchi T, Hayashi Y, Fujii H, Nishida T, Tsujii M, Takehara T (April 2016). "Vitamin K deficiency leads to exacerbation of murine dextran sulfate sodium-induced colitis". J. Gastroenterol. 51 (4): 346–56. doi:10.1007/s00535-015-1112-x. PMID 26314836.
  43. Bodó I, Eikenboom J, Montgomery R, Patzke J, Schneppenheim R, Di Paola J (July 2015). "Platelet-dependent von Willebrand factor activity. Nomenclature and methodology: communication from the SSC of the ISTH". J. Thromb. Haemost. 13 (7): 1345–50. doi:10.1111/jth.12964. PMC 5576173. PMID 25858564.
  44. Lyons SE, Bruck ME, Bowie EJ, Ginsburg D (March 1992). "Impaired intracellular transport produced by a subset of type IIA von Willebrand disease mutations". J. Biol. Chem. 267 (7): 4424–30. PMID 1537829.